Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities
Net (loss)/income	$ (2,847,000)	$ 6,029,000
Adjustments to reconcile net (loss)/income to net cash provided by operating activities:
Depreciation and amortization	3,242,000	2,805,000
Equity-based compensation	1,239,000	(6,781,000)
Non-cash interest expense; amortization of debt costs	106,000	81,000
Changes in assets and liabilities
Taxes receivable	(308,000)	1,790,000
Prepaid expense and other current assets	(555,000)	(111,000)
Other assets	2,008,000	23,000
Accounts payable	(662,000)	(527,000)
Deferred revenue and patient deposits	859,000	575,000
Accrued and other liabilities	(2,214,000)	(519,000)
Net cash provided by operating activities	868,000	3,365,000
Cash flows from investing activities
Purchases of property and equipment, net	(1,901,000)	(1,562,000)
Net cash used in investing activities	(1,901,000)	(1,562,000)
Cash flows from financing activities
Payment on term loan	(1,063,000)	(531,000)
Payments for debt modification	(237,000)	0
Dividends paid to shareholders	0	(13,000.0)
Payment of taxes withheld through vested equity-based compensation	(56,000)	(377,000)
Other financing activity	(293,000)	(175,000)
Net cash provided used in financing activities	(1,649,000)	(1,096,000)
Net (decrease)/increase in cash and cash equivalents	(2,682,000)	707,000
Cash and cash equivalents
Beginning of period	8,235,000	10,262,000
End of period	5,553,000	10,969,000
Supplemental disclosure of cash flow information:
Cash paid for interest	1,521,000	1,478,000
Cash paid for income taxes	0	249,000
Supplemental disclosure of non-cash investing information:
Property and equipment included in accounts payable and accrued expenses	$ 137,000	$ 927,000